ANTIBODY THERAPY FOR MODULATING FUNCTION OF INTESTINAL RECEPTORS AND METHODS OF TREATING DIABETES AND OBESITY
The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.
1 . (canceled)
2 . A pharmaceutical composition comprising an antibody specific for an apical intestinal receptor in the gastrointestinal tract of a patient, wherein the apical intestinal receptor is a sugar receptor or sugar transporter, wherein the pharmaceutical composition is formulated for direct delivery to the gastrointestinal (GI) tract of the patient.
3 . The pharmaceutical composition of claim 2 , wherein the sugar receptor or transporter is selected from: sodium/glucose transporter-1 (SGLT1), glucose transporter-5 (GLUT5), glucose transporter-2 (GLUT2), glucose transporter-7 (GLUT7), sweet taste receptor-1 (T1R1), sweet taste Receptor-2 (T1R2), and sweet taste receptor-3 (T1R3).
4 . The pharmaceutical composition of claim 3 , wherein the sugar receptor or transporter is SGLT1.
5 . A method of treating a metabolic disease in a patient comprising orally or rectally administering to the patient a therapeutically effective amount of the composition of claim 1 .
6 . The method of claim 5 , wherein the metabolic disease is selected from: hyperglycemia, diabetes, impaired glucose tolerance, impaired fasting glycemia, obesity, hyperinsulinemia, hyperlipidemia, hyper-cholesterolemia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia, and gout.
7 . The method of claim 6 , wherein the treatment of diabetes includes complications associated with diabetes selected from: retinopathy, neuropath, nephropathy, ulcer, and macroangiopathy.
8 . The method of claim 5 , wherein the composition is administered before ingesting a substance that may contain glucose or concurrently with the ingestion of a substance that may contain glucose, fructose or a related hexose.
9 . The method of claim 5 , wherein the composition is administered after ingesting a substance that may contain glucose, fructose or a related hexose.